Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
0.7210
-0.0342 (-4.53%)
At close: Mar 28, 2025, 4:00 PM
0.7279
+0.0069 (0.95%)
Pre-market: Mar 31, 2025, 8:39 AM EDT
Seres Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 30.79 | 127.97 | 163.03 | 180 | 116.05 | Upgrade
|
| Short-Term Investments | - | - | 18.31 | 110.7 | 137.57 | Upgrade
|
| Cash & Short-Term Investments | 30.79 | 127.97 | 181.34 | 290.71 | 253.62 | Upgrade
|
| Cash Growth | -75.94% | -29.43% | -37.62% | 14.62% | 167.48% | Upgrade
|
| Receivables | 2.07 | - | - | - | 9.39 | Upgrade
|
| Prepaid Expenses | 5.81 | 8.05 | 13.42 | 12.92 | 5.77 | Upgrade
|
| Other Current Assets | - | 39.4 | - | - | - | Upgrade
|
| Total Current Assets | 38.67 | 175.41 | 194.76 | 303.63 | 268.78 | Upgrade
|
| Property, Plant & Equipment | 92.44 | 108.03 | 133.97 | 36.15 | 22.94 | Upgrade
|
| Long-Term Investments | - | - | - | 0.5 | 49.83 | Upgrade
|
| Other Long-Term Assets | 8.7 | 75.16 | 20.05 | 14.59 | 1.4 | Upgrade
|
| Total Assets | 139.81 | 358.6 | 348.78 | 354.86 | 342.94 | Upgrade
|
| Accounts Payable | 4.08 | 3.64 | 17.44 | 13.74 | 4.02 | Upgrade
|
| Accrued Expenses | 10.72 | 22.51 | 25.07 | 24 | 14.23 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | 0.46 | - | 0.45 | Upgrade
|
| Current Portion of Leases | 8.67 | 5.59 | 3.6 | 6.61 | 5.12 | Upgrade
|
| Current Unearned Revenue | - | - | 4.26 | 16.82 | 22.6 | Upgrade
|
| Other Current Liabilities | 17.75 | 66.92 | 34.77 | 21.1 | - | Upgrade
|
| Total Current Liabilities | 41.22 | 98.66 | 85.6 | 82.26 | 46.42 | Upgrade
|
| Long-Term Debt | - | 101.54 | 50.59 | 24.64 | 24.64 | Upgrade
|
| Long-Term Leases | 82.97 | 91.65 | 107.94 | 17.96 | 10.56 | Upgrade
|
| Long-Term Unearned Revenue | - | - | 92.43 | 87 | 85.57 | Upgrade
|
| Other Long-Term Liabilities | 1.84 | 111.6 | 1.44 | 11.5 | 1 | Upgrade
|
| Total Liabilities | 126.03 | 403.46 | 338 | 223.35 | 168.19 | Upgrade
|
| Common Stock | 0.17 | 0.14 | 0.13 | 0.09 | 0.09 | Upgrade
|
| Additional Paid-In Capital | 991.71 | 933.24 | 875.18 | 745.83 | 723.48 | Upgrade
|
| Retained Earnings | -978.1 | -978.24 | -864.51 | -614.35 | -548.78 | Upgrade
|
| Comprehensive Income & Other | - | - | -0.01 | -0.06 | -0.05 | Upgrade
|
| Total Common Equity | 13.78 | -44.86 | 10.78 | 131.51 | 174.75 | Upgrade
|
| Shareholders' Equity | 13.78 | -44.86 | 10.78 | 131.51 | 174.75 | Upgrade
|
| Total Liabilities & Equity | 139.81 | 358.6 | 348.78 | 354.86 | 342.94 | Upgrade
|
| Total Debt | 91.64 | 198.78 | 162.59 | 49.21 | 40.77 | Upgrade
|
| Net Cash (Debt) | -60.85 | -70.82 | 18.75 | 241.5 | 212.85 | Upgrade
|
| Net Cash Growth | - | - | -92.23% | 13.46% | 325.39% | Upgrade
|
| Net Cash Per Share | -0.39 | -0.55 | 0.17 | 2.63 | 2.67 | Upgrade
|
| Filing Date Shares Outstanding | 174.36 | 151.01 | 126.08 | 92.01 | 91.55 | Upgrade
|
| Total Common Shares Outstanding | 173.01 | 135.04 | 125.22 | 91.89 | 91.46 | Upgrade
|
| Working Capital | -2.55 | 76.75 | 109.17 | 221.37 | 222.36 | Upgrade
|
| Book Value Per Share | 0.08 | -0.33 | 0.09 | 1.43 | 1.91 | Upgrade
|
| Tangible Book Value | 13.78 | -44.86 | 10.78 | 131.51 | 174.75 | Upgrade
|
| Tangible Book Value Per Share | 0.08 | -0.33 | 0.09 | 1.43 | 1.91 | Upgrade
|
| Machinery | 32.92 | 33.09 | 31.58 | 23.61 | 19.89 | Upgrade
|
| Construction In Progress | 0.86 | 1.11 | 3.97 | 1.67 | 0.35 | Upgrade
|
| Leasehold Improvements | 30.95 | 32.49 | 32.47 | 32.93 | 27.98 | Upgrade
|
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.